Nemolizumab is under clinical development by Galderma and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase III drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Nemolizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nemolizumab overview
Nemolizumab (Mitchga) is monoclonal antibody against it is formulated as freeze dried powder, lyophilized powder for solution for subcutaneous route of administration. Mitchga is indicated for the treatment of itching associated with atopic dermatitis (AD) for adults and children 13 years and older.
Nemolizumab (CIM-331) is under development for the treatment of prurigo nodularis, atopic dermatitis, chronic kidney disease associated severe pruritus, prurigo nodularis patients with moderate to severe pruritus and systemic sclerosis (scleroderma). The drug candidate is administered as a subcutaneous solution. It is an anti-IL-31 receptor alpha humanized monoclonal antibody. It is a new molecular entity (NME). It is being developed based on proprietary antibody engineering technology ACT-Ig.
Galderma overview
Galderma provides science-based solutions for skin health. The company’s activities involve the development and distribution of skincare products and medical solutions. Its product portfolio includes prescription drugs, aesthetic solutions, and consumer skincare products. The company’s major brands include Azzalure, Restylane, Sculptra, Cetaphil, and Alastin. Galderma serves its products to a wide range of skin health needs, for the treatment of maintaining healthy skin and rejuvenating aging skin. It distributes through a network of healthcare professionals and retailers, reaching consumers and across various industries. The company has a global presence, operating in over 90 countries. Galderma is headquartered in Lausanne, Lake Geneva, Switzerland.
For a complete picture of Nemolizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
